Related Experiment Video
Updated: Apr 6, 2026
09:28
One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 25, 2010
13.7K
Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain
M Noai1, H Soraoka1, A Kajiwara1
1Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
Acta Neurologica Scandinavica
|July 31, 2015
Summary
Genetic variations in CYP2C19 influence valproic acid-induced weight gain in young females with epilepsy. Loss-of-function alleles were associated with increased BMI and risk of becoming overweight, highlighting a potential pharmacogenetic link.
Area of Science:
- Pharmacogenetics
- Epilepsy Treatment
- Metabolic Research
Background:
- Cytochrome P450 (CYP) 2C19 is crucial for drug and hormone metabolism.
- Hormones influence food intake and energy balance.
- CYP2C19 genetic variations may impact drug-induced metabolic changes.
Purpose of the Study:
- To investigate the association between CYP2C19 polymorphisms and weight gain in young epilepsy patients treated with valproic acid (VPA).
- To compare these effects with carbamazepine (CBZ) treatment.
Main Methods:
- Retrospective longitudinal study of 85 VPA-treated and 93 CBZ-treated young epilepsy patients.
- Analysis of body mass index (BMI) changes and risk of becoming overweight.
- Utilized generalized estimating equations and Kaplan-Meier methods to assess genotype-phenotype associations.
Main Results:
- VPA-treated female patients with CYP2C19 loss-of-function alleles showed significantly greater BMI gaps and a trend towards higher incidence of becoming overweight.
- No significant associations were found in VPA-treated males or in CBZ-treated patients (males and females).
Conclusions:
- This study suggests a link between CYP2C19 genotype and VPA-induced weight gain specifically in female epilepsy patients.
- Further research is warranted to confirm these pharmacogenetic findings and their clinical implications.
More Related Videos
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
199
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
199
01:27Pharmacogenetics of Drug Metabolism: Overview
125
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
125
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
114
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
114
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
887
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
887
01:16Drug toxicity: Idiosyncratic Reactions
171
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
171
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
67
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
67